drugset / Trial / NCT04588818
Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to determine the efficacy and safety of ADA plus MTX for the treatment in non-infectious pediatric panuveitis.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 20 mg | Subcutaneous |
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Methotrexate | Small molecule | 10 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 20 mg/m2 | — |